Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology

[1]  L. Tan,et al.  TREM2 Overexpression has No Improvement on Neuropathology and Cognitive Impairment in Aging APPswe/PS1dE9 Mice , 2016, Molecular Neurobiology.

[2]  S. Strittmatter,et al.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network , 2017, Acta Neuropathologica.

[3]  Ronald C. Petersen,et al.  TYROBP genetic variants in early-onset Alzheimer's disease , 2016, Neurobiology of Aging.

[4]  R. Friedland,et al.  Neuroprotective effect of TREM-2 in ageing and Alzheimer’s disease model , 2016 .

[5]  J. Buxbaum,et al.  Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease , 2016, Genome Medicine.

[6]  J. Grutzendler,et al.  TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy , 2016, Neuron.

[7]  L. Tan,et al.  TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice , 2016, Neuropharmacology.

[8]  C. Alberini,et al.  Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[9]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[10]  D. Holtzman,et al.  TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques , 2016, The Journal of experimental medicine.

[11]  E. Klann,et al.  Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease , 2016, Neurobiology of Aging.

[12]  W. Klein,et al.  Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer’s APP/PSEN1 mice by gene targeting of diabetes/Alzheimer’s-related Sorcs1 , 2016, Acta Neuropathologica Communications.

[13]  L. Tan,et al.  Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice , 2015, Neurobiology of Aging.

[14]  Bin Zhang,et al.  Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1Δexon9 mouse models identifies shared features with human Alzheimer's brain molecular pathology , 2015, Molecular Psychiatry.

[15]  P. Castillo,et al.  APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses , 2015, eLife.

[16]  Keith A. Johnson,et al.  Modulation of TREM2 by CD33: a protein QTL study integrates Alzheimer loci in human monocytes , 2015, Nature Neuroscience.

[17]  Bin Zhao,et al.  Association between Polymorphisms of the AKT1 Gene Promoter and Risk of the Alzheimer's Disease in a Chinese Han Population with Type 2 Diabetes , 2015, CNS neuroscience & therapeutics.

[18]  Taigang He,et al.  Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer’s disease , 2015, Scientific Reports.

[19]  P. De Camilli,et al.  Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques , 2015, Proceedings of the National Academy of Sciences.

[20]  K. Zahs,et al.  Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration. , 2015, Cell reports.

[21]  A. Palmeri,et al.  A key role for TGF-β1 in hippocampal synaptic plasticity and memory , 2015, Scientific Reports.

[22]  R. Ransohoff,et al.  TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models , 2015, The Journal of experimental medicine.

[23]  L. Lue,et al.  Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex , 2015, Neurobiology of Aging.

[24]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[25]  J. Grutzendler,et al.  Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques , 2014, Nature Communications.

[26]  L. Tan,et al.  Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[27]  W. Klein,et al.  Elucidating Molecular Mass and Shape of a Neurotoxic Aβ Oligomer , 2014, ACS chemical neuroscience.

[28]  G. Casadesus,et al.  Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. , 2014, Biochimica et biophysica acta.

[29]  Michelle K. Lupton,et al.  Missense variant in TREML2 protects against Alzheimer's disease , 2014, Neurobiology of Aging.

[30]  Yingyi Wang,et al.  The SIRT2 Polymorphism rs10410544 and Risk of Alzheimer’s Disease: A Meta-analysis , 2014, NeuroMolecular Medicine.

[31]  Magda Tsolaki,et al.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. , 2013, Journal of Alzheimer's disease : JAD.

[32]  M. Harirchian,et al.  Association Study of Cathepsin D Gene Polymorphism in Iranian Patients with Sporadic Late-Onset Alzheimer's Disease , 2013, Dementia and Geriatric Cognitive Disorders.

[33]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[34]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[35]  E. Benarroch.  Microglia , 2013, Neurology.

[36]  C. Holmes,et al.  Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.

[37]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[38]  F. Heppner,et al.  Microglia as Dynamic and Essential Components of the Amyloid Hypothesis , 2013, Neuron.

[39]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[40]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[41]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[42]  H. Choi,et al.  SIRT2 interferes with autophagy-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition , 2012, Neurochemistry International.

[43]  Kenta Moriwaki,et al.  The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.

[44]  M. A. Ikram,et al.  Cathepsin D gene and the risk of Alzheimer's disease: A population-based study and meta-analysis , 2011, Neurobiology of Aging.

[45]  Hélène Marie,et al.  Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.

[46]  M. Mattson,et al.  The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior , 2011, Cell.

[47]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[48]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[49]  Guanghua Xiao,et al.  A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.

[50]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[51]  Christian Neri,et al.  SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis , 2010, Proceedings of the National Academy of Sciences.

[52]  Xinkun Wang,et al.  Selective Neuronal Vulnerability to Oxidative Stress in the Brain , 2010, Front. Ag. Neurosci..

[53]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[54]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[55]  C. Glabe,et al.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.

[56]  Roberto Malinow,et al.  Synaptic AMPA Receptor Plasticity and Behavior , 2009, Neuron.

[57]  N. Durany,et al.  Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.

[58]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[59]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[60]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[61]  A. Triller,et al.  Developmental Neuronal Death in Hippocampus Requires the Microglial CD11b Integrin and DAP12 Immunoreceptor , 2008, The Journal of Neuroscience.

[62]  E. Réal,et al.  Prenatal Activation of Microglia Induces Delayed Impairment of Glutamatergic Synaptic Function , 2008, PloS one.

[63]  G. Lubec,et al.  Barnes maze, a useful task to assess spatial reference memory in the mice , 2007 .

[64]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[65]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[66]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[67]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[68]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[69]  D. Neary,et al.  Genetic associations between cathepsin D exon 2 C→T polymorphism and Alzheimer’s disease, and pathological correlations with genotype , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  Eric H. Chang,et al.  AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[71]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[72]  S. Sajikumar,et al.  Late-associativity, synaptic tagging, and the role of dopamine during LTP and LTD , 2004, Neurobiology of Learning and Memory.

[73]  William M. Mauck,et al.  Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice , 2004, Journal of neurochemistry.

[74]  Bengt Winblad,et al.  Akt activity in Alzheimer's disease and other neurodegenerative disorders , 2004, Neuroreport.

[75]  Maria Blatow,et al.  Ca2+ Buffer Saturation Underlies Paired Pulse Facilitation in Calbindin-D28k-Containing Terminals , 2003, Neuron.

[76]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[77]  B. Blom,et al.  DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. , 2000, Immunity.

[78]  Leena Peltonen,et al.  Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts , 2000, Nature Genetics.

[79]  Y. Ihara,et al.  Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. , 2000, Biochemistry.

[80]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[81]  Detlef Balschun,et al.  A neuromodulatory role of interleukin-1β in the hippocampus , 1998 .

[82]  C. Barnes.  Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. , 1979, Journal of comparative and physiological psychology.

[83]  R. Ransohoff,et al.  Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. , 2016, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[84]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[85]  A. Singleton,et al.  TREM2 Variants in Alz hei mer's Disease , 2012 .

[86]  P. Bertolazzi,et al.  Gene expression biomarkers in the brain of a mouse model for Alzheimer's disease: mining of microarray data by logic classification and feature selection. , 2011, Journal of Alzheimer's disease : JAD.

[87]  Weidong Zhou,et al.  The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[88]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[89]  F. Pitossi,et al.  A neuromodulatory role of interleukin-1beta in the hippocampus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .